Piroxicam cataplasm

A technology of piroxicam and piroxicam, applied in anti-inflammatory agents, non-central analgesics, medical preparations of non-active ingredients, etc., can solve the problem of large drug loading

Inactive Publication Date: 2017-08-11
北京茗泽中和药物研究有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the large amount of drug loaded in the drug reservoir of the hydrogel patch, and it generally takes a long time to apply, the ideal drug release characteristics should be rapid and sustained release, and it can be effective during the entire application cycle while taking effect quickly. Sustained and stable drug release
This point is especially important for the anti-inflammatory drug with larger gastrointestinal side effects such as piroxicam, so providing a kind of piroxicam babu patch capable of rapid and sustained drug release becomes a problem to be solved urgently in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Piroxicam cataplasm
  • Piroxicam cataplasm
  • Piroxicam cataplasm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Pharmacological Example 1 In Vitro Release Experiment

[0020] According to the method provided in the third method (paddle and disk method, used for transdermal patch) in the second appendix XD of the Chinese Pharmacopoeia 2010 edition, the emergency release of the patch obtained in Examples 1 to 6 is measured . The specific method is as follows

[0021] In the test, physiological saline was used as the release medium, and the release medium was added into the dissolution cup, pre-warmed to (32±0.5°C) to remove the protective layer of the cataplasm, cut into a size of 2.5cmx7.5cm, and put it flat into a dialysis bag (molecular weight cut-off 14,000 ), with the release side facing up, placed between two layers of discs, so that the edges of the disc clamp the two ends of the dialysis bag, and then wrap and fix with rubber bands to fix the disc. Take 6mL samples from the dissolution vessel at 10min, 20min, 30min, 45min, 60min, 90min, 2h, 2.5h, 3h and 4h respectively, a...

Embodiment 2

[0022] Pharmacological embodiment 2, in vitro transdermal experiment

[0023] The modified Franz diffusion cell method was used to conduct an in vitro transdermal test with the cataplasm patch prepared in Examples 1-6 and Comparative Examples 1-6, using the abdominal skin of isolated 3-month-old rats as a barrier. The specific experimental method is:

[0024] After 3-month-old healthy rats were anesthetized and killed, the abdominal hair was removed with scissors, the undamaged skin was removed, and the subcutaneous tissue was removed. After washing, they were respectively fixed at the release port of the Franz diffusion cell, and pH 7.4 phosphoric acid was added to the receiving chamber. The buffer is used as a release medium to keep the endothelial layer in close contact with the solution. Put the cataplasm with the protective layer removed on the skin, adjust the water bath so that the temperature of the outer layer is constant at (32±0.5)°C, and the stirring speed is 100r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses piroxicam cataplasm. The piroxicam cataplasm comprises back lining layers, medicine storages and protective layers, and is characterized in that the medicine storages comprise, by weight, 1%-2% of piroxicam, 10%-15% of oil-phase components, 5%-10% of partially neutralized sodium polyacrylate, 15%-20% of glycerol, 1%-1.5% of carbomer 934, 1.5%-2% of hydroxyl propyl methyl celluloses (HPMC), pH (potential of hydrogen) regulators, 0.2%-0.4% of dihydroxyaluminum aminoacetate, 0.1%-0.3% of calcium disodium edetate, 0.2%-0.3% of dimethyl sulfoxide (DMSO), 1%-3% of fillers and the balance water, and the piroxicam is used as an active component; the oil-phase components comprise caprin, Vaseline and lauric acid, a weight ratio of the caprin to the Vaseline to the lauric acid is 1-1.2:0.3-0.4:0.08-0.12, and the piroxicam is dispersed in oil phases; the partially neutralized sodium polyacrylate is used as a water-phase component.

Description

technical field [0001] The invention relates to a piroxicam babu patch. Background technique [0002] Piroxicam (2-methyl-4-hydroxy-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, CAS:36322-90- 4) It is a non-steroidal anti-inflammatory drug with antipyretic and analgesic effects. It is widely used in the analgesic treatment of osteoarthritis and rheumatoid arthritis. It can inhibit the synthesis of prostaglandins in local tissue by inhibiting cyclooxygenase It plays a pharmacological role by reducing and inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. However, because the concentration required to inhibit cyclooxygenase-2 is higher than that required to inhibit cyclooxygenase-1, there are many adverse reactions in the gastrointestinal tract. Traditional oral administration is effective in the treatment of trauma, joints, soft tissues, and muscles. When the pain caused by inflammation requires a large amount of medicine to be tak...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/5415A61K47/14A61K47/18A61K47/12A61P29/00
Inventor 蔡志浩
Owner 北京茗泽中和药物研究有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap